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Edited by Robert BaroukiAbstract Little is known about the role of p38MAPK in human
adipocyte diﬀerentiation. Here we showed that p38MAPK activ-
ity increases during human preadipocytes diﬀerentiation. Phar-
macological inhibition of p38MAPK during adipocyte
diﬀerentiation of primary human preadipocytes markedly re-
duced triglycerides accumulation and adipocyte markers expres-
sion. Cell cycle arrest or proliferation was not aﬀected by
p38MAPK inhibition. Although induction of C/EBPb was not
altered by the p38MAPK inhibitor, its phosphorylation on Thre-
onine188 was decreased as well as PPARc expression. These
results indicate that p38MAPK plays a positive role in human
adipogenesis through regulation of C/EBPb and PPARc factors.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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adipose tissue1. Introduction
Obesity is a signiﬁcant risk factor in numerous diseases, such
as type 2 diabetes and hypertension. Obesity is characterized
by an increase in lipid storage in adipocytes and an increase
in the number of adipocytes. They are derived from a pool
of existing preadipocytes, which are ready to diﬀerentiate when
an appropriate signal is given. Intracellular Mitogen Activated
Protein Kinase (MAPK) signalling pathways are activated by
various stimuli and play a pivotal role in many essential cellu-*Corresponding author. Address: INSERM U 568, Faculte´ de
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doi:10.1016/j.febslet.2007.10.064lar processes such as proliferation, inﬂammation and diﬀeren-
tiation. The MAPK family comprises three groups:
extracellular signal-regulated kinases (ERKs), c-Jun amino-
terminal kinases (JNKs), and p38MAPK [1]. Regarding cellu-
lar diﬀerentiation, the role of MAPKs is extremely complex
and depends on multiple parameters. However, numerous
works clearly demonstrate that MAPK can eﬃciently modu-
late this process [2].
The role of MAPK pathways in adipocytes diﬀerentiation is
not yet fully understood. However, a ﬁne tuning of MAPK
activation seems to be required for adipogenesis. Indeed,
whereas JNK pathway does not seem to be involved directly
in adipocyte diﬀerentiation, both proper activation and inhibi-
tion of ERK pathway seem to be necessary for adipogenesis
from mouse stem cells to adipocytes [3,4]. Furthermore, study
of ERK1 deﬁcient mice revealed a crucial role of this isoform
in adipogenesis in vivo [5]. Opposing roles are described
for p38MAPK in adipocyte diﬀerentiation. Inhibition of
p38MAPK activity in 3T3-L1 ﬁbroblasts blocks their diﬀeren-
tiation in adipocytes and overexpression of a constitutively
active form of MKK6 (upstream activator of p38MAPK) is
suﬃcient to promote adipogenesis [6,7]. In contrast, other re-
ports suggest that p38MAPK activation blocks adipocyte dif-
ferentiation through phosphorylation of transcription factors
such as CHOP or NFATc4 [8–10]. Furthermore, we recently
reported, that p38MAPK plays a negative role in adipogenesis
in several mouse cellular models via inhibition of C/EBPb and
PPARc transcriptional activity [11]. The role of the MAPK in
human adipogenesis has not been investigated yet. Interest-
ingly, there is an up-regulation in the expression of MAPKs
genes, including MKK6 which activates p38MAPK and
ERK1 in human omental adipose tissue from obese patients
[12]. These results suggest that human adipose tissue develop-
ment could require an increase in ERK1 and/or p38MAPK
activities.
In this study, we investigate the requirement for p38MAPK
activity in adipogenesis of human preadipocytes isolated
from subcutaneous and visceral adipose tissues. We show
that p38MAPK inhibition markedly reduces human prea-
dipocyte diﬀerentiation and decreases the phosphorylation
of C/EBPb and the expression of PPARc. These results sug-
gest that p38MAPK activation plays a positive role in human
adipogenesis through regulation of adipogenic transcription
factors.blished by Elsevier B.V. All rights reserved.
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2.1. Isolation and cell culture of human preadipocytes
Abdominal subcutaneous adipose tissue was obtained from patients
undergoing elective surgery in accordance with the guidelines of ethics
committee. Visceral preadipocytes were prepared by Biopredic (Re-
nnes, France) from patients undergoing abdominal surgery. None of
the patients had diabetes or severe systemic illness, and none was tak-
ing medications known to inﬂuence adipose tissue mass, distribution,
or metabolism. Adipose tissue was digested with 1 mg/ml type I colla-
genase (Worthington Biochemical, Freehold, NJ) in Hank’s balanced
salt solution (HBSS), for 45 min at 37 C. The digested tissue was ﬁl-
tered through 250 lm sieves, and isolated cells were centrifuged at
500 · g for 10 min. The cell pellet was incubated in erythrocyte lysis
buﬀer (5.7 mM K2HPO4, pH 7.0, 54 mM NH4Cl, 0.1 mM EDTA) ﬁl-
tered through 25–30 lm sieves and centrifuged at 500 · g for 10 min.
The resulting pellet was washed in HBSS and resuspended in
DMEM/Ham’s F-12 medium (Invitrogen SARL, Cergy Pontoise,
France) containing 15 mM HEPES, 2 mM L-Glutamine, 10% FCS
(Sigma, St Louis, MO, USA), 1% antimycotic solution, ECGS/H-2,
hEGF-5, and HC-500 from supplement pack preadipocyte growth
medium (Promocell, Heidelberg, Germany). The cells were seeded in
12-well collagen-coated plates and grown until conﬂuence at 5% CO2
and 37 C.
Subcutaneous or visceral preadipocytes were induced to diﬀerentiate
in DMEM/Ham’s F12, 15 mM HEPES, 2 mM L-glutamine, and 3%
FCS supplemented with 33 lM D-Biotin, 17 lM panthotenate,
100 nM insulin, 1 lM dexamethasone and for the ﬁrst 3 days of culture
with 0.2 mM 3-isobutyl-1-methylxanthine. To determine the eﬀect of
p38MAPK inhibition on adipocyte diﬀerentiation, cells were treated
at day 0 with 10 lM of the p38MAPK inhibitor PD169316 (Calbio-
chem, La Jolla, CA, USA) or vehicle (DMSO) together with the diﬀer-
entiation medium. Treatments were changed every day for 10–15 days
until cells had accumulated visible lipid droplets. Other inhibitors
SB203580, SP600125 and U0126 were used in the same conditions than
PD169316 at 10 lM and purchased from Calbiochem.P-p38
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Fig. 1. p38MAPK activity increases during adipocyte diﬀerentiation.
Human preadipocytes were diﬀerentiated according to standard
protocol. At the indicated days after the initiation of the diﬀerentia-
tion, the cells were lysed and proteins were resolved by SDS–PAGE
and immunoblotted with the indicated antibody. Representative
immunoblot is shown (upper panel). Results have been normalized
for the amount of p38MAPK and are the means ± S.E.M. of three
diﬀerent experiments (lower panel). *Signiﬁcantly diﬀerent from
p38MAPK activity at day 1 with P < 0.05.2.2. Cell proliferation
Cell proliferation was determined by 3-(4,5-dimethylthiazal-z-yl)-
2,5-diphenylterazolium (MTT) assay. Preadipocytes were seeded in
96-well plates at 5 · 103 cells per well and cultured in DMEM/Ham’s
F-12 containing 10% FBS until the cells attached. When cells reached
conﬂuence, they were treated with diﬀerentiation culture medium and/
or PD169316 for 24 h. The cells were then incubated with MTT for 4 h
at 37 C. The medium was removed and dye formazan crystals were
solubilized in isopropanol with 0.1 mM HCl. Absorbance was mea-
sured at 550 nm.
2.3. Oil-red O staining
Cells were washed in PBS, ﬁxed for 15 min in 0.2% glutaraldehyde in
PBS and stained with six volumes of Oil-red O (0.5% in isopropanol)
and four volumes of H2O for 15 min at room temperature.
2.4. Real-time quantitative PCR
Quantitative RT-PCR was performed with the ABI Prism7000 (Ap-
plied Biosystem) as previously described [11]. The relative amounts of
the diﬀerent mRNAs were quantiﬁed by using the second derivative
maximum method. b2M was used as an invariant control, and the rel-
ative quantiﬁcation for a given gene was corrected to b2M mRNA val-
ues. The results were expressed relative to the control condition, which
was arbitrary assigned a value of 1.C
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Fig. 2. p38MAPK inhibition decreases adipocyte markers expression.
(A and B) Human subcutaneous preadipocytes were diﬀerentiated for
15 days in the presence or absence of PD169316 (10 lM). Whole cell
lysate was analyzed by Western blot for the phosphorylation and
expression of p38MAPK. Expression of tubulin was used as a loading
control (A). In parallel, cells were ﬁxed and stained with Oil-red O to
visualize lipid accumulation (B). (C) Total RNA was analyzed by real
time RT-PCR for the expression of Leptin, Glut4 and Adiponectin
mRNAs. mRNA expression was normalised using b2M RNA levels.
Results are expressed in arbitrary units, with the values without
PD169316 taken as 1 and are the means ± S.E.M. of four indepen-
dent experiments (Sub, Subcutaneous, Om, Omental). *P < 0.05 and
**P < 0.01.
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Antibodies for Western blot analysis were used according to the
manufacturer’s recommendations. Anti-phospho-p38MAPK (Thr180/
Tyr182), p38MAPK, p21, phospho-C/EBPb (Thr188), C/EBPb, phos-
pho-p44/42 MAP Kinase (Thr202/Tyr204), phospho-JNK (Thr183/
Tyr185) and phospho-MAPKAPK-2 (Thr334) were purchased from Cell
Signaling Technology (Berverly MA, USA). Antibodies against
PPARc were purchased from Upstate Biotechnology (Charlottesville,
VA, USA).
2.6. Statistical analysis
All data are expressed as means + S.E.M. Statistical analysis was
performed by Student’s t test. Statistical signiﬁcance was set at a P
lower than 0.05.3. Results
3.1. p38MAPK activity is increased during adipogenesis of
human primary preadipocytes
We ﬁrst studied p38MAPK activation during the diﬀerenti-
ation of human preadipocytes by analysing phospho-
p38MAPK level. Preadipocytes isolated from subcutaneous
fat depots were induced to diﬀerentiate and proteins extracts
were prepared every day from day 1 to day 10. While no diﬀer-
ence was observed in total p38MAPK protein expression level,
the phosphorylation of p38MAPK increased by 2.8-fold 5 days
after the addition of the diﬀerentiation medium and remained
phosphorylated until day 10 (Fig. 1).SB203580SP600125
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Fig. 3. PD169316 speciﬁcally inhibits the p38MAPK pathway and does
diﬀerentiated for 10 days in the presence or absence of diﬀerent MAPK inh
10 lM PD169316 were prepared at diﬀerent day and analyzed by Western blo
of tubulin was used as a loading control. (B) Photos of Oil-red O staining perf
10 lMU0126, SP600125 or SB 203580. (C) Relative mRNA levels of leptin, G
a treatment with SB203580 (10 lM).3.2. PD169316, a speciﬁc p38MAPK inhibitor, decreases human
adipogenesis
To determine whether p38MAPK activation was required for
human adipocytes diﬀerentiation, preadipocytes were induced
to diﬀerentiate for ten days in the absence or presence of
PD169316 (10 lM), a potent and highly speciﬁc inhibitor of
p38MAPKactivity.As shown inFig. 2A, treatment of preadipo-
cytes with PD169316 resulted in the inhibition of the p38MAPK
phosphorylation. Importantly, preadipocytes treated with
PD169316 throughout the diﬀerentiation protocol accumulated
less lipid (indicated by Oil-red O stain) compared to untreated
preadipocytes (Fig. 2B) and they retained a ﬁbroblastic mor-
phology. The same experiment was performed in omental pre-
adipocytes and lead to the same results (data not shown). To
conﬁrm the inhibitory eﬀect of PD169316 on preadipocytes dif-
ferentiation, the expression of speciﬁc adipocyte genes such as
adiponectin, GLUT4 and leptin was determined by quantitative
real time RT-PCR. As illustrated in Fig. 2C, the expression of
those genes was markedly reduced by the p38MAPK inhibitor
in preadipocytes from both subcutaneous (Sub) and omental
(Om) origin. Taken together, these results indicate that
p38MAPK activity is required for the diﬀerentiation of preadi-
pocytes isolated from subcutaneous and visceral fat depots.
3.3. PD169316 speciﬁcally inhibits the p38MAPK pathway
during human preadipocyte diﬀerentiation
To determine the speciﬁcity of PD169316 towards the
p38MAPK pathway, we analysed the phosphorylation of theptin Glut4 adiponectin
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and JNK during the diﬀerentiation in presence or not of the
inhibitor. As expected PD169316 lead to a strong inhibition
of MAPKAPK2 phosphorylation, whereas the inhibitor did
not aﬀect the kinetic of phosphorylation of ERK and JNK
(Fig. 3A). It is noteworthy that the three MAPK pathways
have diﬀerent pattern of phosphorylation during adipogenesis.
These results show that PD169316 is speciﬁc of the p38MAPK
pathway and does not aﬀect the other MAPKs.
To conﬁrm the role of the p38MAPK pathway in human
adipocyte diﬀerentiation, we treated preadipocytes with
10 lM SB203580 another inhibitor of the kinase. SB203580
inhibited triglyceride accumulation while SP600125 (JNK
inhibitor) and the U0126 (inhibitor of the ERK pathway)
did not inhibit adipocyte diﬀerentiation as shown after Oil-
red O staining (Fig. 3B). We analysed the expression of speciﬁc
adipocyte genes such as adiponectin, GLUT4 and leptin and
showed that SB203580 similarly to PD169316 strongly dimin-
ished the level of adipocytes mRNA (Fig. 3C).
All together these results show that the use of two speciﬁc
inhibitors of p38MAPK strongly diminished human adipocyte
diﬀerentiation. V (
0
20
CTRL DM DM
+
PD169316
Fig. 4. p38MAPK is not required for proliferation and cell cycle arrest
of human preadipocytes. (A) Human subcutaneous preadipocytes were
diﬀerentiated in the absence or presence of PD169316 (10 lM). On the
indicated days after the initiation of the diﬀerentiation, the cells were
lysed and proteins were resolved by SDS–PAGE and immunoblotted
with an anti-p21 antibody. Expression of tubulin was used as a loading
control. (A) representative immunoblot and quantiﬁcation of three
independent experiments are shown. (B) Human subcutaneous pre-
adipocytes were treated or not (CTRL) with the diﬀerentiation
medium (DM), in absence or presence of PD169316 and 24 h later
cell viability was evaluated by MTT assay. Means ± S.E.M. of six
independent experiments are shown.3.4. p38MAPK inhibition decreases C/EBPb phosphorylation
and PPARc expression
We then investigated which steps of adipogenesis were
altered by p38MAPK inhibition. Because adipocyte diﬀerenti-
ation ﬁrst requires cell cycle arrest, we determined whether
inhibition of p38MAPK could interfere with this process. To
this aim, we analysed the expression of p21, a protein required
for cell cycle arrest and known to be regulated by p38MAPK
[13]. We observed that p21 protein level gradually increased 3
days after the addition of the diﬀerentiation medium suggest-
ing that cells are arrested (Fig. 4A). Addition of PD169316
did not aﬀect this increase in the expression of p21 suggesting
that the inhibition of p38MAPK does not interfere with the
cell cycle arrest occurring during the ﬁrst stages of adipocyte
diﬀerentiation. By using the MTT method, we quantiﬁed via-
ble cells 2 days after the addition of the diﬀerentiation medium
in presence or absence of PD169316 (Fig. 4B). We observed
that the diﬀerentiation cocktail did not signiﬁcantly alter the
proliferation of the human preadipocytes in agreement with
previous reports showing that there is no mitotic clonal expan-
sion in human primary preadipocytes [14]. Importantly, addi-
tion of PD169316 to the diﬀerentiation medium had no eﬀect
on the percentage of viable cells indicating that the inhibition
of adipocyte diﬀerentiation induced by PD169316 treatment is
not due to cell death or a change in the proliferation rate.
Expression and transcriptional activity of C/EBPb are in-
duced during the initial steps of diﬀerentiation. C/EBPb pro-
teins are activated by phosphorylation on Thr188 within the
two ﬁrst days of the diﬀerentiation process [15]. We analysed
the eﬀect of PD169316 on Thr188 phosphorylation of C/EBPb
in preadipocytes three and ﬁve days post-diﬀerentiation. While
C/EBPb protein expression level was decreased by the inhibi-
tion of p38MAPK (Fig. 5A), its phosphorylation was signiﬁ-
cantly diminished in human preadipocytes on day 3 and to a
less extend on day 5 of the diﬀerentiation (Fig. 5A and B). Be-
cause, it is well known that C/EBPb activation regulates
PPARc expression during adipogenesis, we analysed PPARc
expression by Western blot analysis. The results revealed thatPD169316 treatment decreased PPARc expression on days 3
and 5 of diﬀerentiation (Fig. 5A and B). These results suggest
that p38MAPK inhibition blocks human preadipocyte diﬀer-
entiation through C/EBPb and PPARc regulation.4. Discussion
Both positive and negative role of p38MAPK have been de-
scribed for the diﬀerentiation of mouse adipocyte and its role
in human adipogenesis remains largely unknown. In order to
clarify the role of p38MAPK during human adipogenesis, we
examined this pathway in preadipocytes isolated from human
subcutaneous and visceral adipose tissue. Our results show
that p38MAPK phosphorylation gradually increased during
adipogenesis in both subcutaneous and visceral preadipocytes,
showing a correlation between p38MAPK activation and adi-
pocyte diﬀerentiation. We then demonstrated that the block-
ade of p38MAPK activity using the p38MAPK speciﬁc
inhibitor PD169316 leads to a decrease in human preadipocyte
diﬀerentiation. Moreover, this inhibitor does not aﬀect the
activity nor the kinetic of activation of other MAPK which
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Fig. 5. p38MAPK inhibition decreases C/EBPb phosphorylation and PPARc expression. Subcutaneous preadipocytes were induced to diﬀerentiate,
in presence or absence of PD169316 (10 lM). (A and B) At days 3 and 5, whole cell lysates were prepared and proteins probed with anti-phospho-C/
EBPb, anti-C/EBPb, anti-PPARc and anti-p38MAPK antibodies. Means ± S.E.M. of three diﬀerent experiments are shown. * PD169316 signiﬁcant
eﬀect compared to control (CTRL) with P < 0.05.
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p38MAPK. In agreement with Patel et al., we found that
SB203580 reduced signiﬁcantly the level of lipid accumulation
in human preadipocytes [16]. Similarly, this inhibitor reduced
3T3-L1 cells diﬀerentiation [6,7]. In contrast, we have recently
shown that p38MAPK activity decreased during mouse pre-
adipocytes diﬀerentiation and its inhibition increases adipo-
genesis [11]. All these data suggest that, depending on cell
types or species, the consequences of p38MAPK inhibition
on the machinery involved in the program of adipocyte diﬀer-
entiation are diﬀerent.
We show here that the kinetic of activation of ERK and
JNK are diﬀerent compared to p38MAPK, furthermore, inhi-
bition of these pathways does not inhibit triglyceride accumu-
lation. These results are in agreement with the literature [16]
and seem to emphasize the speciﬁc role of p38MAPK in
human adipogenesis. However, it would be interesting to study
more speciﬁcally the role of other MAPKs in human adipocyte
diﬀerentiation.
Our results suggest that C/EBPb is one of the factors that
could be diﬀerentially aﬀected by p38MAPK inhibition. In-
deed, we found that C/EBPb phosphorylation on Threonine188
is reduced following inhibition of p38MAPK activity in human
primary preadipocytes undergoing diﬀerentiation. Interest-
ingly, the lack of diﬀerentiation observed in 3T3-L1 adipocytes
following p38MAPK inhibition is also associated with a lower
phosphorylation of C/EBPb protein. Conversely, in mouse
preadipocytes, inhibition of p38MAPK activity increased C/
EBPb phosphorylation at Threonine188 and augmented adipo-
cyte diﬀerentiation. Several reports have shown that phosphor-
ylation of this site is required for the activation of C/EBPb
suggesting that the inhibitory eﬀect observed, is due, at least
in part, to an inhibition of C/EBPb function. C/EBPb stimu-
lates mitotic clonal expansion, a process required for mouse
preadipocytes diﬀerentiation [17]. However, there are no evi-dences that mitotic clonal expansion is required for human adi-
pocyte diﬀerentiation in vitro. In agreement, we did not
observe any increase in the cell number following addition of
the diﬀerentiation medium. Further, our observation that
PD169316 has no eﬀect on p21 protein expression, suggests
that cells are arrested and that p38MAPK does not interfere
with this process. Another key role of C/EBPb in the diﬀeren-
tiation program is the induction of the expression regulators of
terminal adipogenesis such as PPARc. C/EBPb phosphoryla-
tion on Threonine188 is required for acquisition of DNA bind-
ing function and transactivation of downstream targets [18].
Our data are consistent with a role of p38MAPK in the pos-
translationnal activation of C/EBPb because the induction
of PPARc is markedly aﬀected following treatment with
PD169316.
The mechanisms explaining the opposite eﬀect of p38MAPK
inhibition on mouse and human primary preadipocytes adipo-
genesis still need to be determined. One possible explanation is
that C/EBPb is directly phosphorylated by p38MAPK in hu-
man preadipocytes as well as in 3T3-L1 cells. In contrast, in
mouse preadipocytes the observation that inhibition of
p38MAPK increases the phosphorylation of C/EBPb strongly
suggests that other kinases are responsible for this event. The
site encompassing Threonine188 is a consensus site for both
ERK1/2 and GSK3 which indeed phosphorylate C/EBPb
[15,19]. One can imagine that in mouse preadipocytes
p38MAPK pathway could exert a negative tone on other C/
EBPb kinases that would be removed by p38MAPK inhibitor.
It is also possible that depending on the cellular context, co-
factors that regulate the adipogenic transcription factors C/
EBPb and PPARc could be regulated in diﬀerent ways follow-
ing p38MAPK inhibition.
In conclusion, our study establishes a positive role of
p38MAPK pathway in human adipogenesis through regula-
tion of C/EBPb and PPARc and reveals that adipocyte diﬀer-
5596 M. Aouadi et al. / FEBS Letters 581 (2007) 5591–5596entiation is controlled by diﬀerent mechanisms in human and
mouse. The origin of these discrepancies requires further inves-
tigation that may be of interest to deﬁne a potential role for
p38MAPK inhibitors in the ﬁght against obesity.
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